Completed PHASE3 INTERVENTIONAL 2-arm NCT00292253

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

A Randomized, Multicenter, Parallel Group, Open-label Study Comparing the Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing Remitting MS Patients

Sponsor: EMD Serono

Conditions Multiple Sclerosis, Relapsing-remitting

Interventions Rebif® via Rebiject™Mini Rebif® via manual injections

Updated 6 times since 2017 Last updated: Aug 4, 2013 Started: Jan 31, 2001 Primary completion: Dec 31, 2002 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00292253, this PHASE3 trial focuses on Multiple Sclerosis, Relapsing-remitting and remains completed. Sponsored by EMD Serono, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EMD Serono
Merck Serono International SA

Data source: EMD Serono

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.